

**Your reference**  
**Our reference**  
**Date**

September 26, 2023

**Changes to Janus Henderson Capital Funds plc (“JHCF”) and the Underlying Funds (as defined below)**

**Zurich Assurance Ltd**  
(a company incorporated in England and Wales with limited liability)

**Zurich Life Insurance (Hong Kong) Limited**  
(a company incorporated in Hong Kong with limited liability)

25-26/F, One Island East  
18 Westlands Road  
Island East, Hong Kong

Website: www.zurich.com.hk

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

We accept full responsibility for the accuracy of the content of this document. Unless otherwise stated, the terms used but not otherwise defined in this letter shall have the same meanings as those defined in JHCF’s latest Hong Kong offering documents (comprising the prospectus for JHCF and/or supplements for the Underlying Funds as amended from time to time (the “Prospectus”), the Important Notice to Residents of Hong Kong (“INRHK”) and the relevant Product Key Fact Statements (“KFS”), collectively the “Hong Kong Offering Documents”).

Dear valued customer,

We are writing to let you know about the changes to JHCF and the Underlying Funds. You have invested in one of the investment choices corresponding to the Underlying Funds, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

**Which investment choices are affected?**

<b>Name and code of the investment choice (Individually, the “Investment Choice”; collectively, the “Investment Choices”)</b>	<b>Name of the corresponding underlying fund (Individually, the “Underlying Fund”; collectively, the “Underlying Funds”)</b>	<b>Applicable scheme (Collectively, the “Schemes”)</b>
Janus Henderson Capital Funds plc - Janus Henderson Global Life Sciences Fund (code: O4USD)	Janus Henderson Capital Funds plc - Janus Henderson Global Life Sciences Fund	<ul style="list-style-type: none"> <li>• Magnitude</li> <li>• Matterhorn</li> </ul>
Janus Henderson Capital Funds plc - Janus Henderson Global Real Estate Equity Income Fund (code: O5USD)	Janus Henderson Capital Funds plc - Janus Henderson Global Real Estate Equity Income Fund	
Janus Henderson Capital Funds plc - Janus Henderson Balanced Fund (code: NZUSD)	Janus Henderson Capital Funds plc - Janus Henderson Balanced Fund	
Janus Henderson Capital Funds plc - Janus Henderson Balanced Fund (Dis) (code: TLUSD)		Matterhorn

### **What is happening?**

We have been notified by JHCF of certain changes to JHCF and the Underlying Funds.

Unless otherwise specified below, these changes are reflected in the revised Hong Kong Offering Documents dated on September 11, 2023 (the “Effective Date”).

#### **1. Update to the template pre-contractual disclosure of Janus Henderson Capital Funds plc - Janus Henderson Global Real Estate Equity Income Fund (“this Underlying Fund” for the purpose of this section) for the purpose of SFDR**

The template pre-contractual disclosure of this Underlying Fund for the purpose of SFDR has been updated from the Effective Date to reflect the following:

- (a) The exclusionary screens, which are coded into the compliance module of the Sub-Investment Adviser’s order management system, are implemented on both a pre- and post- trade basis enabling the Sub-Investment Adviser to block any proposed transactions in an excluded security and identify any changes to the status of holdings when third-party data is periodically updated;
- (b) This Underlying Fund will not invest in fossil gas and / or nuclear energy related activities that comply with the EU Taxonomy; and
- (c) Janus Henderson’s “ESG Investment Policy” can be found at [www.janushenderson.com/esg-governance](http://www.janushenderson.com/esg-governance)<sup>1</sup>.

Please refer to the updated “Annex II Template pre-contractual disclosure” in the Prospectus for further details. The “Annex II Template pre-contractual disclosure” for this Underlying Fund is appended to the Prospectus.

#### **2. Updates in relation to when-issued, delayed-delivery and forward commitment securities**

The Prospectus has been updated from the Effective Date to reflect the following:

- (a) In the statement permitting an Underlying Fund to invest up to 25% of its net asset value in securities purchased on a “when-issued”, “delayed-delivery”, “forward commitment” or “to be announced” basis, a reference to “TBA” has been added since “to be announced” securities are often referred to by this acronym; and
- (b) The proposed rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”), include certain mandatory margin requirements for TBA commitments and collateralised mortgage obligations which, in some circumstances, may require an Underlying Fund to also post collateral. These collateral requirements may increase costs associated with an Underlying Fund’s participation in the TBA market.

#### **3. Update to the investment policy of Janus Henderson Capital Funds plc - Janus Henderson Global Life Sciences Fund (“this Underlying Fund” for the purpose of this section)**

Currently, the investment policy of this Underlying Fund as disclosed in the Prospectus states that this Underlying Fund may invest to a lesser degree in other types of securities including preference shares, Government Securities, Debt Securities, warrants and securities convertible into equities when the relevant Sub-Investment Adviser perceives an opportunity for capital growth from such securities.

The investment policy of this Underlying Fund as disclosed in the Prospectus has been updated from the Effective Date to include private equities as an example of such other types of securities.

---

<sup>1</sup> This website has not been reviewed by the SFC and may contain information relating to funds not authorized by the SFC and not available to Hong Kong investors.

#### 4. Other miscellaneous updates

The following miscellaneous updates to the Hong Kong Offering Documents:

- (a) Addition of “Inflation/Deflation risk” as a general investment risk which may affect the Underlying Funds in the section entitled “Risk Factors and Special Considerations” of the Prospectus;
- (b) Update to reflect the change in the reference to “Key Investor Information Document” to “Key Investor Document” in the Hong Kong Offering Documents;
- (c) Removal of The Egyptian Exchange (EGX), the Moscow Exchange (MOEX) and The Saint Petersburg Stock Exchange as Regulated Markets from Appendix 2 of the Prospectus;
- (d) Addition of The Zagreb Stock Exchange as a Regulated Market for Croatia in Appendix 2 of the Prospectus;
- (e) Update to the list of delegates appointed by J.P. Morgan SE, Dublin Branch in Appendix 5 of the Prospectus; and
- (f) Other miscellaneous and editorial updates.

The changes outlined above will not have a material impact on the investment strategy, portfolio composition, or risk profile of the Underlying Funds of JHCF. There are no new fees, charges or increases in existing fees or charges borne by the Underlying Funds because of these changes. There will not be a material adverse impact on the rights or interests of the investors of the Underlying Funds. There will be no material change in the operation and/or manner in which the Underlying Funds are being managed.

Investors may obtain the latest Hong Kong Offering Documents, the Articles, as well as the annual and semi-annual reports of JHCF at [www.janushenderson.com](http://www.janushenderson.com)<sup>1</sup>.

#### **What does this mean to you?**

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 2968 2383 or contact us via <http://www.zurich.com.hk/en/customer-services/contact-us> and we will be happy to help.

Yours faithfully,

Zurich Life Insurance (Hong Kong) Limited  
(a company incorporated in Hong Kong with limited liability)

***Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.***

---

<sup>1</sup> This website has not been reviewed by the SFC and may contain information relating to funds not authorized by the SFC and not available to Hong Kong investors.

## 有關駿利亨德森資產管理基金（「JHCF」）及該等相關基金（定義見下文）之變更

此乃重要函件，務請您即時垂注。您如對本函件的内容有任何疑問，請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。除非另有訂明，否則本函件所載詞彙應與JHCF最新的香港銷售文件（包括JHCF的招股說明書及/或該等相關基金的補充文件（經不時修訂）（「招股說明書」）、致香港居民重要通告（「致香港居民重要通告」）及相關產品資料概要（「產品資料概要」），統稱「香港銷售文件」）所載者具有相同涵義。

親愛的客戶：

我們謹此致函通知您有關JHCF及該等相關基金的變更。您已投資於該等相關基金相應的其中一個投資選項，其列於下表「受影響的投資選項」中「投資選項的名稱及代碼」一欄。

### 受影響的投資選項

投資選項（各稱為「該投資選項」，統稱為「該等投資選項」）的名稱及代碼	相應的相關基金（各稱為「該相關基金」，統稱為「該等相關基金」）名稱	適用計劃（統稱「計劃」）
駿利亨德森資產管理基金 - 駿利亨德森環球生命科技基金 (代碼：O4USD)	駿利亨德森資產管理基金 - 駿利亨德森環球生命科技基金	<ul style="list-style-type: none"> <li>瑞豐投資計劃</li> <li>瑞承投資計劃</li> </ul>
駿利亨德森資產管理基金 - 駿利亨德森環球房地產股票入息基金 (代碼：O5USD)	駿利亨德森資產管理基金 - 駿利亨德森環球房地產股票入息基金	
駿利亨德森資產管理基金 - 駿利亨德森平衡基金 (代碼：NZUSD)	駿利亨德森資產管理基金 - 駿利亨德森平衡基金	
駿利亨德森資產管理基金 - 駿利亨德森平衡基金（派息） (代碼：TLUSD)		瑞承投資計劃

### 修訂事項

JHCF已通知我們有關JHCF及該等相關基金作出的若干變更。

除非下文另有註明，否則該等變更已反映於日期為2023年9月11日（「生效日期」）的經修訂香港銷售文件。

#### 1. 更新駿利亨德森資產管理基金 - 駿利亨德森環球房地產股票入息基金（就本節而言，稱為「此該相關基金」）因應SFDR的訂約前披露範本

此該相關基金因應SFDR的訂約前披露範本已自生效日期起作出更新，以反映如下：

- 排除篩選（被編入副投資顧問的指示管理系統的合規模塊）在交易前及交易後執行，讓副投資顧問能夠阻止任何被排除證券的建議交易，並在第三方數據定期更新時識別持倉狀況的任何變動；
- 此該相關基金將不會投資於符合歐盟分類的化石天然氣及/或核能相關活動；及
- 駿利亨德森的「ESG投資政策」可於[www.janushenderson.com/esg-governance](http://www.janushenderson.com/esg-governance)<sup>1</sup>取得。

請參閱招股說明書中經更新的「附件II訂約前披露範本」，以了解進一步詳情。此該相關基金的「附件II訂約前披露範本」隨附於招股說明書。

<sup>1</sup> 此網站並未經證監會審閱，並可能載有關於未經證監會認可及不可向香港投資者提供的基金之資料。

## 2. 有關當發行時、遞延交付及遠期承諾證券的更新

招股說明書已自生效日期起作出更新，以反映如下：

- (a) 在批准該相關基金將其資產淨值最多25%投資於按「當發行時」、「遞延交付」、「遠期承諾」或「將予公佈」的基準購買的證券之陳述中，已加插有關「TBA」的提述，因為「將予公佈」證券通常以此首字母縮略詞提述；及
- (b) 美國金融業監管局（「FINRA」）的建議規則包括對TBA承擔及有抵押按揭債務的若干強制性保證金要求，在某些情況下，可能要求該相關基金亦提供抵押品。該等抵押品要求可能會增加該相關基金參與TBA市場的相關成本。

## 3. 更新駿利亨德森資產管理基金 - 駿利亨德森環球生命科技基金（就本節而言，稱為「此該相關基金」）的投資政策

目前，在招股說明書披露的此該相關基金的投資政策訂明，若有關的副投資顧問認為，其他類別證券包括優先股、政府證券、債務證券、認股權證及可轉換為股票的證券可帶來資本增值機會時，此該相關基金可在較小程度上投資於該等證券。

在招股說明書披露的此該相關基金的投資政策已自生效日期起作出更新，以包括私募股票作為該等其他類別證券的例子。

## 4. 其他雜項更新

有關香港銷售文件的以下雜項更新：

- (a) 在招股說明書「風險因素和特別考慮」一節內加插「通脹 / 通縮風險」作為可能影響該等相關基金的一般投資風險；
- (b) 更新以反映香港銷售文件中「主要投資者資訊文件」之提述更改為「主要投資者文件」；
- (c) 自招股說明書的附錄二刪除埃及股票交易所（EGX）、莫斯科（Moscow）股票交易所（MOEX）及聖彼德堡（Saint Petersburg）股票交易所作為受監管市場；
- (d) 於招股說明書的附錄二加插薩格勒布（Zagreb）證券交易所作為克羅地亞的受監管市場；
- (e) 更新招股說明書附錄五由J.P. Morgan SE都柏林分行委任的代表名單；及
- (f) 其他雜項及編輯更新。

上文概述的變更將不會對JHCF的該等相關基金的投資策略、投資組合構成或風險概況產生重大影響。該等相關基金不會因該等變更而承擔新的費用、收費或增加的現有費用或收費。將不會對該等相關基金投資者的權利或利益造成重大不利影響。該等相關基金的運作及 / 或管理方式將不會發生重大變更。

投資者可從[www.janushenderson.com](http://www.janushenderson.com)<sup>1</sup>免費取得JHCF最新的香港銷售文件、《組織章程細則》，以及年度及半年度報告。

### 對您產生的影響

如您在考慮上述變更後仍繼續投資於該等投資選項，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選項，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選項的指示，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選項的建議。有關本公司投資選項（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

<sup>1</sup> 此網站並未經證監會審閱，並可能載有關於未經證監會認可及不可向香港投資者提供的基金之資料。

如您對本函件或投資選項中的投資有任何疑問，請聯絡您的持牌保險中介人。您亦可致電+852 2968 2383或經由<http://www.zurich.com.hk/zh-hk/customer-services/contact-us>聯絡我們，我們將樂意為您效勞。

蘇黎世人壽保險（香港）有限公司  
（於香港註冊成立之有限公司）  
2023年9月26日

*註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。*